{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T18:15:53Z","timestamp":1774548953523,"version":"3.50.1"},"reference-count":148,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Malignant pleural mesothelioma (MPM) is a rare and aggressive malignant disease affecting the mesothelium, commonly associated to asbestos exposure. The current therapeutic actions, based on cisplatin\/pemetrexed treatment, are limited due to the late stage at which most patients are diagnosed and to the intrinsic chemo-resistance of the tumor. Another relevant point is the absence of approved therapies in the second line setting following progression of MPM after chemotherapy. Considering the poor prognosis of the disease and the fact that the incidence of this tumor is expected to increase in the next decade, novel therapeutic approaches are urgently needed. In the last few years, several studies have investigated the efficacy and safety of immune-checkpoint inhibitors (ICIs) in the treatment of unresectable advanced MPM, and a number of trials with immunotherapeutic agents are ongoing in both first line and second line settings. In this review, we describe the most promising emerging immunotherapy treatments for MPM (ICIs, engineered T cells to express chimeric antigen receptors (CARs), dendritic cells (DCs) vaccines), focusing on the biological and immunological features of this tumor as well as on the issues surrounding clinical trial design.<\/jats:p>","DOI":"10.3390\/cancers13112793","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T11:12:13Z","timestamp":1622805133000},"page":"2793","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Immunotherapeutic Approaches in Malignant Pleural Mesothelioma"],"prefix":"10.3390","volume":"13","author":[{"given":"Rita","family":"Terenziani","sequence":"first","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8357-1073","authenticated-orcid":false,"given":"Silvia","family":"Zoppi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3291-6668","authenticated-orcid":false,"given":"Claudia","family":"Fumarola","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0601-7244","authenticated-orcid":false,"given":"Roberta","family":"Alfieri","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5728-7899","authenticated-orcid":false,"given":"Mara","family":"Bonelli","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"12611","DOI":"10.1073\/pnas.1006542107","article-title":"Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation","volume":"107","author":"Yang","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Cornelissen, R., Lievense, L.A., Maat, A.P., Hendriks, R.W., Hoogsteden, H.C., Bogers, A.J., Hegmans, J.P., and Aerts, J.G. (2014). Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0106742"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e1009285","DOI":"10.1080\/2162402X.2015.1009285","article-title":"The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers","volume":"4","author":"Ujiie","year":"2015","journal-title":"Oncoimmunology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.tox.2015.10.005","article-title":"Enhancement of regulatory T cell-like suppressive function in MT-2 by long-term and low-dose exposure to asbestos","volume":"338","author":"Ying","year":"2015","journal-title":"Toxicology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","article-title":"CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection","volume":"59","author":"Yamada","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bcp.2016.07.012","article-title":"New therapeutic strategies for malignant pleural mesothelioma","volume":"123","author":"Bonelli","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: Recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3389\/fonc.2020.00343","article-title":"Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?","volume":"10","author":"Cantini","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s00262-016-1844-3","article-title":"CTLA-4 in mesothelioma patients: Tissue expression, body fluid levels and possible relevance as a prognostic factor","volume":"65","author":"Roncella","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.jtho.2019.03.029","article-title":"Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma","volume":"14","author":"Salaroglio","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative Molecular Characterization of Malignant Pleural Mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/eji.201646875","article-title":"Immune checkpoints and their inhibition in cancer and infectious diseases","volume":"47","author":"Dyck","year":"2017","journal-title":"Eur. J. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ctrv.2015.09.006","article-title":"Targeting immune checkpoints: New opportunity for mesothelioma treatment?","volume":"41","author":"Marcq","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1084\/jem.185.3.393","article-title":"CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics","volume":"185","author":"Bodian","year":"1997","journal-title":"J. Exp. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: A common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"12468","DOI":"10.18632\/oncotarget.3487","article-title":"Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model","volume":"6","author":"Wu","year":"2015","journal-title":"Oncotarget"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e1494111","DOI":"10.1080\/2162402X.2018.1494111","article-title":"Combination immune checkpoint blockade as an effective therapy for mesothelioma","volume":"7","author":"Fear","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1158\/1535-7163.MCT-11-1014","article-title":"CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma","volume":"11","author":"Wu","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Lesterhuis, W.J., Salmons, J., Nowak, A.K., Rozali, E.N., Khong, A., Dick, I.M., Harken, J.A., Robinson, B.W., and Lake, R.A. (2013). Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0061895"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: An open-label, single-arm, phase 2 trial","volume":"14","author":"Morra","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: An open-label, single-arm, phase 2 study","volume":"3","author":"Morra","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): A multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"97671","DOI":"10.18632\/oncotarget.18311","article-title":"Soluble PD-1 and PD-L1: Predictive and prognostic significance in cancer","volume":"8","author":"Zhu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma","volume":"13","author":"Zimmerman","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)","volume":"25","author":"Okada","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): A multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): Results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"ref_29","unstructured":"Squibb, B.M. (2021, January 14). OPDIVO (Nivolumab) Prescribing Information. US Food and Drug Administration. Available online: https:\/\/packageinserts.bms.com\/pi\/pi_opdivo.pdf."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s13063-018-2602-y","article-title":"CONFIRM: A double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: Study protocol for a randomised controlled trial","volume":"19","author":"Fennell","year":"2018","journal-title":"Trials"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Fennell, D., Ottensmeier, C., Califano, R., Hanna, G., Ewings, S., Hill, K., Wilding, S., Danson, S., Nye, M., and Steele, N. (2021). PS01.11 Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial. J. Thorac. Oncol., 16.","DOI":"10.1016\/j.jtho.2021.01.323"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e705","DOI":"10.1016\/j.cllc.2018.05.001","article-title":"A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol","volume":"19","author":"Fujimoto","year":"2018","journal-title":"Clin. Lung Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.cllc.2020.10.005","article-title":"A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol","volume":"22","author":"Shah","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S1077","DOI":"10.1016\/j.annonc.2020.08.1441","article-title":"1898P A phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma: JME-001","volume":"31","author":"Fujimoto","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"v931","DOI":"10.1093\/annonc\/mdz394.091","article-title":"A multicentre randomized phase III trial comparing pembrolizumab (P) vs. single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial","volume":"30","author":"Popat","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): Preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial","volume":"5","author":"Hassan","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"9003","DOI":"10.1200\/JCO.2020.38.15_suppl.9003","article-title":"PrE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)\u2014A PrECOG LLC study","volume":"38","author":"Forde","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"S705","DOI":"10.1016\/j.annonc.2020.08.1141","article-title":"1021O Safety and antitumor activity of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with mesothelioma which is relapsed or refractory to standard therapies","volume":"31","author":"Millward","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1084\/jem.171.5.1393","article-title":"LAG-3, a novel lymphocyte activation gene closely related to CD4","volume":"1171","author":"Triebel","year":"1990","journal-title":"J. Exp. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/BF00241263","article-title":"Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand","volume":"39","author":"Huard","year":"1994","journal-title":"Immunogenetics"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0165-2478(97)00170-3","article-title":"LAG-3 does not define a specific mode of natural killing in human","volume":"61","author":"Huard","year":"1998","journal-title":"Immunol. Lett."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1002\/eji.200526090","article-title":"Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells","volume":"35","author":"Kisielow","year":"2005","journal-title":"Eur. J. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1182\/blood-2003-01-0273","article-title":"MHC class II signal transduction in human dendritic cells induced by a natural ligand, the LAG-3 protein (CD223)","volume":"102","author":"Andreae","year":"2003","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2567.2005.02145.x","article-title":"The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells","volume":"115","author":"Triebel","year":"2005","journal-title":"Immunology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"688","DOI":"10.4049\/jimmunol.174.2.688","article-title":"Negative regulation of T cell homeostasis by lymphocyte activation gene-3 (CD223)","volume":"174","author":"Workman","year":"2005","journal-title":"J. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/imr.12519","article-title":"LAG3 (CD223) as a cancer immunotherapy target","volume":"276","author":"Andrews","year":"2017","journal-title":"Immunol. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","article-title":"Role of LAG-3 in regulatory T cells","volume":"21","author":"Huang","year":"2004","journal-title":"Immunity"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e001014","DOI":"10.1136\/jitc-2020-001014","article-title":"LAG-3: From molecular functions to clinical applications","volume":"8","author":"Maruhashi","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1084\/jem.176.2.327","article-title":"Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens","volume":"176","author":"Baixeras","year":"1992","journal-title":"J. Exp. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"18748","DOI":"10.1074\/jbc.M311227200","article-title":"Characterization of a novel C-type lectin-like gene, LSECtin: Demonstration of carbohydrate binding and expression in sinusoidal endothelial cells of liver and lymph node","volume":"279","author":"Liu","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"176","DOI":"10.18632\/genesandcancer.180","article-title":"The promising immune checkpoint LAG-3: From tumor microenvironment to cancer immunotherapy","volume":"9","author":"Long","year":"2018","journal-title":"Genes Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"89722","DOI":"10.18632\/oncotarget.21113","article-title":"Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients","volume":"8","author":"Marcq","year":"2017","journal-title":"Oncotarget"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Marcq, E., Van Audenaerde, J.R.M., De Waele, J., Merlin, C., Pauwels, P., van Meerbeeck, J.P., Fisher, S.A., and Smits, E.L.J. (2021). The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3. Cancers, 13.","DOI":"10.3390\/cancers13020282"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/415536a","article-title":"Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease","volume":"415","author":"Monney","year":"2002","journal-title":"Nature"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.molmed.2005.06.008","article-title":"The TIM gene family regulates autoimmune and allergic diseases","volume":"11","author":"Meyers","year":"2005","journal-title":"Trends Mol. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.coi.2011.12.005","article-title":"Tim-3, a negative regulator of anti-tumor immunity","volume":"24","author":"Anderson","year":"2012","journal-title":"Curr. Opin. Immunol."},{"key":"ref_58","first-page":"127","article-title":"Tim-3, Lag-3, and TIGIT","volume":"410","author":"Joller","year":"2017","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1172\/JCI45138","article-title":"Allograft rejection is restrained by short-lived TIM-3+PD-1+Foxp3+ Tregs","volume":"122","author":"Gupta","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1002\/eji.201344392","article-title":"Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells","volume":"44","author":"Gautron","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/ni1271","article-title":"The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity","volume":"6","author":"Zhu","year":"2005","journal-title":"Nat. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"15659","DOI":"10.1038\/srep15659","article-title":"Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer","volume":"5","author":"Kang","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nature13848","article-title":"CEACAM1 regulates TIM-3-mediated tolerance and exhaustion","volume":"517","author":"Huang","year":"2015","journal-title":"Nature"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/ni.2376","article-title":"Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1","volume":"13","author":"Chiba","year":"2012","journal-title":"Nat. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1182\/blood-2008-10-185884","article-title":"Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation","volume":"113","author":"Nakayama","year":"2009","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.4049\/jimmunol.0903059","article-title":"T cell\/transmembrane, Ig, and mucin-3 allelic variants differentially recognize phosphatidylserine and mediate phagocytosis of apoptotic cells","volume":"184","author":"DeKruyff","year":"2010","journal-title":"J. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Gao, X., Zhu, Y., Li, G., Huang, H., Zhang, G., Wang, F., Sun, J., Yang, Q., Zhang, X., and Lu, B. (2012). TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0030676"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI59806","article-title":"IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma","volume":"122","author":"Yang","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J. Exp. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","article-title":"Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia","volume":"117","author":"Zhou","year":"2011","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e1261241","DOI":"10.1080\/2162402X.2016.1261241","article-title":"Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma","volume":"6","author":"Marcq","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: Moving beyond PD-1 and CTLA-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1084\/jem.20100619","article-title":"VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses","volume":"208","author":"Wang","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.4049\/jimmunol.1100660","article-title":"Cutting edge: A monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models","volume":"187","author":"Flies","year":"2011","journal-title":"J. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/2326-6066.CIR-14-0072","article-title":"VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy","volume":"2","author":"Lines","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/cmi.2017.148","article-title":"The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation","volume":"15","author":"Xu","year":"2018","journal-title":"Cell Mol. Immunol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/cei.13415","article-title":"VISTA: Coming of age as a multi-lineage immune checkpoint","volume":"200","author":"ElTanbouly","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"eaay0524","DOI":"10.1126\/science.aay0524","article-title":"VISTA is a checkpoint regulator for naive T cell quiescence and peripheral tolerance","volume":"367","author":"ElTanbouly","year":"2020","journal-title":"Science"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/imm.13001","article-title":"VSIG-3 as a ligand of VISTA inhibits human T-cell function","volume":"156","author":"Wang","year":"2019","journal-title":"Immunology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41586-019-1674-5","article-title":"VISTA is an acidic pH-selective ligand for PSGL-1","volume":"574","author":"Johnston","year":"2019","journal-title":"Nature"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00262-017-1968-0","article-title":"Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma","volume":"66","author":"Wu","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e1293215","DOI":"10.1080\/2162402X.2017.1293215","article-title":"The novel negative checkpoint regulator VISTA is expressed in gastric carcinoma and associated with PD-L1\/PD-1: A future perspective for a combined gastric cancer therapy?","volume":"6","author":"Boger","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s00262-018-2227-8","article-title":"Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors","volume":"67","author":"Xie","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_84","first-page":"3465","article-title":"Expression of V-domain immunoglobulin suppressor of T cell activation is associated with the advanced stage and presence of lymph node metastasis in ovarian cancer","volume":"16","author":"Liao","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Zhang, M., Pang, H.J., Zhao, W., Li, Y.F., Yan, L.X., Dong, Z.Y., and He, X.F. (2018). VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4435-1"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1158\/1078-0432.CCR-17-2542","article-title":"Spatially Resolved and Quantitative Analysis of VISTA\/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer","volume":"24","author":"Yu","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00262-018-2169-1","article-title":"VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival","volume":"67","author":"Kuklinski","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1073\/pnas.1811067116","article-title":"Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer","volume":"116","author":"Blando","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"S758","DOI":"10.1016\/j.jtho.2018.08.1295","article-title":"P2.06-40 VISTA is Highly Expressed in Malignant Pleural Mesothelioma (MPM) and Independent of PD-L1 Expression","volume":"13","author":"Zauderer","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41379-019-0364-z","article-title":"V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma","volume":"33","author":"Muller","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Lee, J.J., Powderly, J.D., Patel, M.R., Brody, J., Hamilton, E.P., Infante, J.R., Falchook, G.S., Wang, H.W., Adams, L., and Gong, L. (2017). Phase 1 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in patients (pts) with advanced solid tumor or lymphomas. J. Clin. Oncol., 35.","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS3099"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"v405","DOI":"10.1093\/annonc\/mdx376.007","article-title":"CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study","volume":"28","author":"Powderly","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"S757","DOI":"10.1016\/j.jtho.2019.08.1625","article-title":"P2.06-07 Phase 1 Study of CA-170: First-in-Class Small Molecule Targeting VISTA\/PD-L1 in Patients with Malignant Pleural Mesothelioma","volume":"14","author":"Zauderer","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Klampatsa, A., Haas, A.R., Moon, E.K., and Albelda, S.M. (2017). Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM). Cancers, 9.","DOI":"10.3390\/cancers9090115"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2017.04.004","article-title":"CAR T-cell therapy for lung cancer and malignant pleural mesothelioma","volume":"187","author":"Zeltsman","year":"2017","journal-title":"Transl. Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"Hamieh","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrc971","article-title":"Targeting tumours with genetically enhanced T lymphocytes","volume":"3","author":"Sadelain","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1002\/acg2.84","article-title":"TRUCKS, the fourth-generation CAR T cells: Current developments and clinical translation","volume":"3","author":"Chmielewski","year":"2020","journal-title":"Adv. Cell Gene Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1158\/1078-0432.CCR-12-0628","article-title":"CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma","volume":"18","author":"Rivera","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/2051-1426-2-25","article-title":"Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells","volume":"2","author":"Beard","year":"2014","journal-title":"J. Immunother. Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.canlet.2017.02.015","article-title":"Intracavitary \u2018T4 immunotherapy\u2019 of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells","volume":"393","author":"Klampatsa","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s004320050171","article-title":"Hepatocyte growth factor\/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma","volume":"124","author":"Tolnay","year":"1998","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/carcin\/bgp097","article-title":"Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells","volume":"30","author":"Kawaguchi","year":"2009","journal-title":"Carcinogenesis"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/0008-5472.CAN-04-4567","article-title":"Functional analysis of c-Met\/hepatocyte growth factor pathway in malignant pleural mesothelioma","volume":"66","author":"Jagadeeswaran","year":"2006","journal-title":"Cancer Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1042\/BST20150252","article-title":"The role of the HGF\/Met axis in mesothelioma","volume":"44","author":"Thayaparan","year":"2016","journal-title":"Biochem. Soc. Trans."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e1363137","DOI":"10.1080\/2162402X.2017.1363137","article-title":"CAR T-cell immunotherapy of MET-expressing malignant mesothelioma","volume":"6","author":"Thayaparan","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-11-2614","article-title":"Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients","volume":"18","author":"Servais","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/1078-0432.CCR-13-1862","article-title":"Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma","volume":"20","author":"Kachala","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin Immunotherapy for Cancer: Ready for Prime Time?","volume":"34","author":"Hassan","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","article-title":"Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1200\/JCO.2019.37.15_suppl.2511","article-title":"Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent","volume":"37","author":"Adusumilli","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1479-5876-11-187","article-title":"Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells","volume":"11","author":"Schuberth","year":"2013","journal-title":"J. Transl. Med."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Petrausch, U., Schuberth, P.C., Hagedorn, C., Soltermann, A., Tomaszek, S., Stahel, R., Weder, W., and Renner, C. (2012). Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1). BMC Cancer, 12.","DOI":"10.1186\/1471-2407-12-615"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.annonc.2020.10.474","article-title":"Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: First report of FAPME, a phase I clinical trial","volume":"32","author":"Hiltbrunner","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1164\/rccm.200909-1465OC","article-title":"Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma","volume":"181","author":"Hegmans","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.201508-1573OC","article-title":"Extended Tumor Control after Dendritic Cell Vaccination with Low-Dose Cyclophosphamide as Adjuvant Treatment in Patients with Malignant Pleural Mesothelioma","volume":"193","author":"Cornelissen","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1158\/1078-0432.CCR-17-2522","article-title":"Autologous Dendritic Cells Pulsed with Allogeneic Tumor Cell Lysate in Mesothelioma: From Mouse to Human","volume":"24","author":"Aerts","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"280","DOI":"10.21037\/tlcr.2019.05.05","article-title":"A multicenter, randomized, phase II\/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial","volume":"8","author":"Belderbos","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1242\/dev.153163","article-title":"Wilms\u2019 tumour 1 (WT1) in development, homeostasis and disease","volume":"144","author":"Hastie","year":"2017","journal-title":"Development"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s00262-010-0871-8","article-title":"WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer","volume":"59","author":"Krug","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.imlet.2018.01.011","article-title":"Therapeutic cancer vaccines: From initial findings to prospects","volume":"196","author":"Song","year":"2018","journal-title":"Immunol. Lett."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s12026-017-8931-1","article-title":"Dendritic cell-based immunotherapy: A basic review and recent advances","volume":"65","author":"Constantino","year":"2017","journal-title":"Immunol. Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1251\/bpo62","article-title":"Development of a new protocol for 2-day generation of mature dendritic cells from human monocytes","volume":"5","author":"Obermaier","year":"2003","journal-title":"Biol. Proced. Online"},{"key":"ref_124","first-page":"6451","article-title":"Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine","volume":"61","author":"Banchereau","year":"2001","journal-title":"Cancer Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"566","DOI":"10.4049\/jimmunol.165.1.566","article-title":"Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo","volume":"165","author":"Pulendran","year":"2000","journal-title":"J. Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.4161\/onci.21494","article-title":"Trial watch: Dendritic cell-based interventions for cancer therapy","volume":"1","author":"Galluzzi","year":"2012","journal-title":"Oncoimmunology"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1164\/rccm.200501-057OC","article-title":"Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells","volume":"171","author":"Hegmans","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1600-065X.2010.00980.x","article-title":"DNA vaccines: An historical perspective and view to the future","volume":"239","author":"Liu","year":"2011","journal-title":"Immunol. Rev."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.4161\/21645515.2014.980686","article-title":"DNA vaccine for cancer immunotherapy","volume":"10","author":"Yang","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.coi.2011.03.007","article-title":"Tumor vaccination using messenger RNA: Prospects of a future therapy","volume":"23","author":"Kreiter","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"794528","DOI":"10.1155\/2015\/794528","article-title":"RNA-Based Vaccines in Cancer Immunotherapy","volume":"2015","author":"McNamara","year":"2015","journal-title":"J. Immunol. Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3389\/fonc.2017.00179","article-title":"Oncolytic Viral Therapy for Mesothelioma","volume":"7","author":"Pease","year":"2017","journal-title":"Front. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2174\/1568009617666170222125035","article-title":"Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects","volume":"18","author":"Msaouel","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3389\/fonc.2019.00564","article-title":"The Oncolytic Virus dl922-947 Triggers Immunogenic Cell Death in Mesothelioma and Reduces Xenograft Growth","volume":"9","author":"Iannuzzi","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jtho.2019.12.128","article-title":"Frequent Homozygous Deletions of Type I Interferon Genes in Pleural Mesothelioma Confer Sensitivity to Oncolytic Measles Virus","volume":"15","author":"Delaunay","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/j.jtho.2020.03.007","article-title":"Oncolytic Viral Therapy for Malignant Pleural Mesothelioma","volume":"15","author":"Yang","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/j.jtho.2020.04.011","article-title":"Reply to: Oncolytic Viral Therapy for Malignant Pleural Mesothelioma","volume":"15","author":"Jean","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"77872","DOI":"10.18632\/oncotarget.20845","article-title":"Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: Expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1","volume":"8","author":"Eguchi","year":"2017","journal-title":"Oncotarget"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Hastie, N. (2016). WT1 Mutation in Childhood Cancer. The Wilms\u2019 Tumor (WT1) Gene: Methods and Protocols, Springer.","DOI":"10.1007\/978-1-4939-4023-3"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"7483","DOI":"10.1158\/1078-0432.CCR-17-2169","article-title":"A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma","volume":"23","author":"Zauderer","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.1158\/1078-0432.CCR-19-0070","article-title":"Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma","volume":"25","author":"Hassan","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Yang, H., Xu, D., Yang, Z., Yao, F., Zhao, H., Schmid, R.A., and Peng, R.W. (2020). Systematic Analysis of Aberrant Biochemical Networks and Potential Drug Vulnerabilities Induced by Tumor Suppressor Loss in Malignant Pleural Mesothelioma. Cancers, 12.","DOI":"10.3390\/cancers12082310"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.cell.2016.11.005","article-title":"The Hippo Pathway Kinases LATS1\/2 Suppress Cancer Immunity","volume":"167","author":"Moroishi","year":"2016","journal-title":"Cell"},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Yang, H., Hall, S.R.R., Sun, B., Zhao, L., Gao, Y., Schmid, R.A., Tan, S.T., Peng, R.W., and Yao, F. (2021). NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma. Cancers, 13.","DOI":"10.3390\/cancers13071561"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1758835920971421","DOI":"10.1177\/1758835920971421","article-title":"Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma","volume":"12","author":"Yang","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e2025109","DOI":"10.1001\/jamanetworkopen.2020.25109","article-title":"Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors","volume":"3","author":"Shao","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/cncr.33433","article-title":"Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies","volume":"127","author":"Hu","year":"2021","journal-title":"Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/11\/2793\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:10:44Z","timestamp":1760163044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/11\/2793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,4]]},"references-count":148,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["cancers13112793"],"URL":"https:\/\/doi.org\/10.3390\/cancers13112793","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,4]]}}}